BahramabadiR, DabiriS, IranpourM, et al.TLR4: an important molecule participating in either anti-human papillomavirus immune responses or development of its related cancers. Viral Immunol, 2019; 32:417–423.
2.
CaoB, WangY, WenD, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe COVID-19. New Eng J Med 2020 (in press).
3.
ContiP, GallengaCE, TetèG, et al. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1. J Biol Regul Homeost Agents 2020 (in press).
4.
ContiP, RonconiG, CaraffaA, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents 2020 (in press).
5.
ContiP, and YounesA. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection. J Biol Regul Homeost Agents 2020 (in press).
6.
GaoJ, TianZ, and YangX. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trend 2020 (in press).
7.
IsogawaM, RobekMD, FuruichiY, et al.Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol, 2005; 79:7269–7272.
8.
Karimi-GoogheriM, and ArababadiMK. TLR3 plays significant roles against hepatitis B virus. Mol Biol Rep, 2014; 41:3279–3286.
9.
KimballA, KruegerJ, SullivanT, et al.IMO-3100, an antagonist of Toll-like receptor (TLR) 7 and TLR9, demonstrates clinical activity in psoriasis patients with 4 weeks of treatment in a Phase 2a trial. J Invest Dermatol, 2013; 133:S26.
10.
KritasSK, RonconiG, CaraffaA, et al. Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J Biol Regul Homeost Agents 2020 (in press).
11.
PatelMC, ShireyKA, PletnevaLM, et al.Novel drugs targeting Toll-like receptors for antiviral therapy. Future Virol, 2014; 9:811–829.
12.
PatraMC, and ChoiS. Recent progress in the development of Toll-like receptor (TLR) antagonists. Expert Opinion Ther Patent, 2016; 719:730–26.
13.
Perrin-CoconL, Aublin-GexA, SestitoSE, et al.TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infection. Sci Rep, 2017; 7:40791.
14.
SchwarzK, StorniT, ManolovaV, et al.Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol, 2003; 33:1465–1470.
15.
SepehriZ, KianiZ, AlavianSM, et al.The link between TLR7 signaling and hepatitis B virus infection. Life Sci, 2016; 158:63–69.
16.
SunR, SunL, BaoM, et al.A human microsatellite DNA-mimicking oligodeoxynucleotide with CCT repeats negatively regulates TLR7/9-mediated innate immune responses via selected TLR pathways. Clin Immunol, 2010; 134:262–276.
17.
Zare-BidakiM, Tsukiyama-KoharaK, and ArababadiMK. Toll-like receptor 4 and hepatitis B infection: molecular mechanisms and pathogenesis. Viral Immunol, 2014; 27:321–326.
18.
ZhaoS, GaoN, QiH, et al.Suppressive effects of sunitinib on a TLR activation-induced cytokine storm. Eur J Pharmacol, 2019; 854:347–353.
